EpimAb latest East Asian biotech to ship asset West

In the latest example of a trend in which VC-backed U.S. start-ups are snapping up innovation from East Asian biotechs, Shanghai-based EpimAb has out-licensed one of its five early-stage clinical bispecifics to stealthy Foresite newco Vignette.

The asset, BCMAxCD3 bispecific EMB-06, is the first program EpimAb Biotherapeutics Inc. developed with its T cell engager platform, which combines the company’s Fabs-in-Tandem-Immunoglobulin (FIT-Ig) bispecific technology with an in-house CD3 panel...